Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis

Efstathios Kastritis, Ioannis Papassotiriou, Giampaolo Merlini, Paolo Milani, Evangelos Terpos, Marco Basset, Athanasios Akalestos, Francesca Russo, Erasmia Psimenou, Filia Apostolakou, Maria Roussou, Maria Gavriatopoulou, Evangelos Eleutherakis-Papaiakovou, Despina Fotiou, Dimitrios C. Ziogas, Elektra Papadopoulou, Constantinos Pamboucas, Meletios A. Dimopoulos, Giovanni Palladini

Blood (2018) 131 (14): 1568–1575.

https://doi.org/10.1182/blood-2017-12-819904

Published: 2018

Includes: Supplemental data

Journal Articles

Efficacy of Lenalidomide As Salvage Therapy for Patients with AL Amyloidosis

Blood (2017) 130 (Supplement 1): 3118.

https://doi.org/10.1182/blood.V130.Suppl_1.3118.3118

Published: 2017

Journal Articles

Addition of Cyclophosphamide and Higher Doses of Dexamethasone Do Not Improve Outcomes of Patients with AL Amyloidosis Treated with Bortezomib

Efstathios Kastritis, MD, Maria Gavriatopoulou, Maria Roussou, Despina Fotiou, Dimitrios Ziogas, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Ioannis Panagiotidis, Erasmia Psimenou, Elektra Papadopoulou, Constantinos Pamboucas, Efstathios Manios, MD, Harikleia Gakiopoulou, MD, Anna Tasidou, MD, Stavroula Giannouli, Evangelos Terpos, MD PhD, Meletios A Dimopoulos

Blood (2016) 128 (22): 4500.

https://doi.org/10.1182/blood.V128.22.4500.4500

Published: 2016

Journal Articles

Growth Differentiation Factor-15 (GDF-15) Is a New Biomarker with Independent Prognostic Significance for Survival and Renal Outcomes in Different Cohorts of Patients with Light Chain (AL) Amyloidosis

Efstathios Kastritis, MD, Giampaolo Merlini, MD, Ioannis Papassotiriou, PhD, Paolo Milani, MD, Evangelos Terpos, Marco Basset, MD, Athanasios Akalestos, Francesca Russo, Erasmia Psimenou, Filia Apostoloakou, Maria Roussou, Maria Gavriatopoulou, Despina Fotiou, Dimitrios Ziogas, Constantinos Pamboucas, Elektra Papadopoulou, Meletios A Dimopoulos, Giovanni Palladini, MD PhD

Blood (2016) 128 (22): 648.

https://doi.org/10.1182/blood.V128.22.648.648

Published: 2016

Journal Articles

Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis

Efstathios Kastritis, Ioannis Papassotiriou, Evangelos Terpos, Maria Roussou, Maria Gavriatopoulou, Anna Komitopoulou, Chrysanthi Skevaki, Evangelos Eleutherakis-Papaiakovou, Constantinos Pamboucas, Erasmia Psimenou, Efstathios Manios, Stavroula Giannouli, Marianna Politou, Harikleia Gakiopoulou, Elektra Papadopoulou, Kimon Stamatelopoulos, Anna Tasidou, Meletios A. Dimopoulos

Blood (2016) 128 (3): 405–409.

https://doi.org/10.1182/blood-2016-02-702696

Published: 2016

Includes: Supplemental data

Journal Articles

Prospective Evaluation of Blood Pressure Monitoring and Baroreceptor Reflex Sensitivity (BRS) in Patients with AL Amyloidosis: Prognostic and Pathophysiologic Implications

Efstathios Kastritis, MD, Maria Roussou, Despoina Fotiou, Dimitrios Ziogas, Maria Gavriatopoulou, Kimon Stamatelopoulos, Constantinos Pamboucas, Elektra Papadopoulou, Fotios Michas, Aikaterini Lykka, Evangelos Terpos, Meletios A. Dimopoulos, Efstathios Manios

Blood (2015) 126 (23): 3054.

https://doi.org/10.1182/blood.V126.23.3054.3054

Published: 2015

Journal Articles

Growth Differentiation Factor-15 in Patients with Light Chain (AL) Amyloidosis Has Independent Prognostic Significance and Adds Prognostic Information Related to Risk of Early Death and Renal Outcomes

Efstathios Kastritis, MD, Ioannis Papassotiriou, PhD, Evangelos Terpos, Athanassios Akalestos, Erasmia Psimenou, Filia Apostolakou, Maria Roussou, Maria Gavriatopoulou, Elisavet Kaldara, Evangelos Eleutherakis-Papaiakovou, Despoina Kalapanida, Constantinos Pamboucas, Evangelos Kostis, Sofoklis Kontogiannis, Savvas Th. Toumanidis, Ioannis Boletis, Meletios A. Dimopoulos

Blood (2014) 124 (21): 306.

https://doi.org/10.1182/blood.V124.21.306.306

Published: 2014

Journal Articles

High Bone Turnover Is Present in Patients with Primary Systemic (AL) Amyloidosis and Increased Osteoprotegerin Identifies Patients with Poor Survival within Mayo Stage 1 Disease

Efstathios Kastritis, MD, Maria Gavriatopoulou, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Maria Roussou, Constantinos Pamboucas, Savvas Th. Toumanidis, Evangelos Terpos, Meletios A. Dimopoulos

Blood (2014) 124 (21): 2028.

https://doi.org/10.1182/blood.V124.21.2028.2028

Published: 2014

Journal Articles

Hemodynamic, Functional and Structural Markers of Vascular Involvement in Primary Systemic Light Chain (AL) Amyloidosis

Kimon Stamatelopoulos, Marita Lyka, Christos Papamichail, Maria Roussou, Maria Gavriatopoulou, Constantinos Pamboucas, Evangelos Terpos, Meletios A. Dimopoulos, Efstathios Kastritis, MD

Blood (2014) 124 (21): 2029.

https://doi.org/10.1182/blood.V124.21.2029.2029

Published: 2014

Journal Articles

Elevated Serum Levels Of Von Willebrand Factor (vWF) Predict For Early Death and Shorter Survival In Patients With Primary Systemic Light Chain (AL) Amyloidosis Independently Of Cardiac Biomarkers

Efstathios Kastritis, Ioannis Papassotiriou, Evangelos Terpos, Alexandra Gougoutsi, Nikolaos Simos, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Dimitrios Chiotis, Georgios Amentas, Maria Kavasi, Constantinos Pamboucas, Erasmia Psimenou, Savvas Th. Toumanidis, Maria Roussou, Meletios A. Dimopoulos, MD

Blood (2013) 122 (21): 3194.

https://doi.org/10.1182/blood.V122.21.3194.3194

Published: 2013

NARROW

Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis

Efficacy of Lenalidomide As Salvage Therapy for Patients with AL Amyloidosis

Addition of Cyclophosphamide and Higher Doses of Dexamethasone Do Not Improve Outcomes of Patients with AL Amyloidosis Treated with Bortezomib

Growth Differentiation Factor-15 (GDF-15) Is a New Biomarker with Independent Prognostic Significance for Survival and Renal Outcomes in Different Cohorts of Patients with Light Chain (AL) Amyloidosis

Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis

Prospective Evaluation of Blood Pressure Monitoring and Baroreceptor Reflex Sensitivity (BRS) in Patients with AL Amyloidosis: Prognostic and Pathophysiologic Implications

Growth Differentiation Factor-15 in Patients with Light Chain (AL) Amyloidosis Has Independent Prognostic Significance and Adds Prognostic Information Related to Risk of Early Death and Renal Outcomes

High Bone Turnover Is Present in Patients with Primary Systemic (AL) Amyloidosis and Increased Osteoprotegerin Identifies Patients with Poor Survival within Mayo Stage 1 Disease

Hemodynamic, Functional and Structural Markers of Vascular Involvement in Primary Systemic Light Chain (AL) Amyloidosis

Elevated Serum Levels Of Von Willebrand Factor (vWF) Predict For Early Death and Shorter Survival In Patients With Primary Systemic Light Chain (AL) Amyloidosis Independently Of Cardiac Biomarkers

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only